Toxicity of taxoids in adjuvant/neoadjuvant therapy in patients with breast cancer

• Autores: L. Carrillo Acevedo, Raquel Marin Gorricho, Andrea Casajús Navasal, Inmaculada Jiménez Pulido, R. García Muñoz, A. Serrano Pérez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 20, Nº. 1, 2018, págs. 24-30
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objectives: To determine the incidence and severity of adverse events associated with treatment with taxoids in the adjuvant/neoadjuvant breast cancer. To describe and compare the toxicity profile of docetaxel and paclitaxel. Method: Prospective observational study in the San Pedro Hospital of Logroño from January to June 2014. Adverse events were collected in each of the chemotherapy cycles of adjuvant/neoadjuvant treatment of breast cancer in women 〉18 years. Adverse events were recorded in the cycle of greatest severity and were classified according to the NCI CTCAE v4.0. We collected personal, anthropometric and clinical data. The chi-square test was performed to assess the safety profile of both taxoids used (SPSS IBM21). Results: Fifty patients completed the study: 54% received docetaxel and 46% paclitaxel. All had some adverse event and 46% experienced serious adverse events. The total number of adverse events was 437, the most severe being neutropenia (7.3%) and neurotoxicity (3.9%). Women treated with paclitaxel experienced more hematological toxicity and neurotoxicity. However, patients treated with docetaxel showed greater changes in laboratory parameters and hypersensitivity reactions. Conclusions: The incidence and severity of adverse events detected match the literature. Most adverse events were treatable with supportive measures and they ceased at the end of treatment. Paclitaxel and docetaxel have similar toxicity profiles with certain distinguishing characteristics. The addition of trastuzumab to taxoids did not increase toxicity significantly